about   CII home   shop   checkout

 
 
 
 
 
 
 
Register button 
 
 

Upcoming Global Web Symposia 

eLearning Archives 


Impact of High-Content Analysis on Regenerative Medicine

 

Tuesday, December 13, 2011
11:00 am-12:00 pm EST
Sponsored by Thermo Scientific logo 

 

Please join us for a complimentary Web Symposium, scheduled before Cambridge Healthtech Institute’s Ninth Annual High-Content Analysis meeting, January 10-13, 2012, in San Francisco. Please visit www.HighContentAnalysis.com for additional information.

High-content analysis has become a widely adopted tool in life science research with applications ranging from target validation, through drug screening, to toxicology and basic cell biology research. Join Professor Donald Zack, Johns Hopkins School of Medicine, and researchers from Thermo Fisher Scientific as we explore the application of our latest developments in high-content technology and their impact on the search for new therapies for degenerative diseases as well as research into stem cells for regenerative medicine.

11:00-11:05 Chairperson’s Introduction
Mark Collins, Ph.D., Director, Global Marketing, LSR-Cellomics, Thermo Fisher Scientific&

11:05-11:25 Use of HCS to Identify Lead Compounds for the Treatment of Retinal Degenerative Disease
Donald J. Zack, Ph.D., Professor of Genetic Engineering and Molecular Ophthalmology, The Wilmer Eye Institute, Johns Hopkins School of Medicine
Glaucoma is a neurodegenerative disease, anticipated to blind nearly 80 million people by 2020, in which retinal ganglion cells (RGCs), the projection neurons that transmit vision from the retina to the brain, are injured and die, partially as a result of increased intraocular pressure (IOP). Current therapies all act by lowering IOP. Unfortunately, lowering IOP can produce undesirable side effects and/or be difficult to achieve. Moreover, in some patients, RGC loss continues despite significant IOP reduction. Lacking are “neuroprotective” agents that directly interfere with the cell death process in RGCs. The development of safe and efficacious neuroprotective agents could improve glaucoma therapy by complementing the currently available IOP treatment options. Similarly, in the retinal degenerative diseases, which are mostly untreatable, there is slow and progressive loss of photoreceptor cells, and this cell loss often results in blindness. In an effort to develop novel and more effective treatment approaches for these diseases, we have been pursuing a High-Content Screening (HCS) approach to screen small molecule libraries for novel neuroprotective molecules that can promote the survival of cultured primary mouse and rat retinal neurons. For these studies, we have utilized a variety of cell-based assays built upon the Cellomics Arrayscan VTI Reader. We have identified several protein kinase inhibitors (PKIs) that are highly neuroprotective for retinal neurons, and have shown that these PKIs are active both in vitro and in vivo. Additionally, we have developed an siRNA-based approach to identify some of the biologically relevant neuroprotective PKIs.

11:25-11:45 Investigating Differentiation and Pluripotency in Stem Cell Colonies Using Multidimensional Imaging on the Thermo Scientific ArrayScan Infinity HCS Reader
Richik Ghosh, Ph.D., Director, Research & Applications, LSR-Cellomics, Thermo Fisher Scientific
With the increase in research into stem cells, high-content analysis is being applied to complex stem cell morphologies and 2-D and 3-D micro-environments. These more complex assays pose challenges for image acquisition; namely, the samples are often thicker and more heterogeneous (e.g., stem cells are on a feeder layer rather than a layer of cells on the bottom of a microplate, so new tools are needed to analyze this kind of biology). The Thermo Scientific ArrayScan Infinity HCS Reader is an evolution of the flagship Thermo Scientific ArrayScan VTI HCS Reader, integrating an innovative confocal microscopy module and a range of software enhancements to provide users with a variety of multidimensional imaging capabilities. This webinar will demonstrate that biological assay results can be significantly improved by choosing the appropriate image acquisition mode. The integration of these modes into an automated high-content imaging platform extends the benefits of high content into new areas of cell biology, such as stem cells, tissues and complex morphological structures.

11:45-12:00 Q&A with the audience 

About the speakers:
Richik Ghosh, Ph.D., is the Director of Research & Applications in the Thermo Fisher Scientific Cellomics Business Unit.  Dr. Ghosh has over 25 years experience developing and applying quantitative fluorescence microscopy-based imaging technologies to different areas of cell biology.  He joined Cellomics, Inc. (now part of Thermo Fisher Scientific) 13 years ago in 1998, and has led various research and development teams that developed key HCS cell-based imaging assay tools.  Before joining Cellomics he was on the faculties of Columbia University, and then Cornell University’s Medical College in New York City, where he managed microscopy imaging facilities and used quantitative fluorescence microscopy to do research into different areas of cell biology.  Dr. Ghosh received his B.S., M.S. and Ph.D. from Cornell University in Applied Physics specializing in Biophysics, and did postdoctoral research in cell biology at Columbia University.

Donald J. Zack, M.D., Ph.D., is the Guerrieri Professor of Genetic Engineering and Molecular Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University. He is also a professor in the Departments of Molecular Biology and Genetics, Neuroscience, and the Institute of Genetic Medicine. Dr. Zack graduated from the Albert Einstein College of Medicine in 1984, where he received a medical degree and a Ph.D. in molecular immunology, under the mentorship of Dr. Matthew Scharff. After a year of internship, Dr. Zack completed a three-year residency training program in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard University. In 1988, he moved to Johns Hopkins where he pursued specialty training in glaucoma under the direction of Dr. Harry Quigley, and molecular biology postdoctoral work under the direction of Dr. Jeremy Nathans. Dr. Zack was appointed Assistant Professor at Hopkins in 1991, Associate Professor in 1997, and Professor in 2001. Dr. Zack has published over 160 peer-reviewed journal articles and has won a number of awards, including the Alcon Research Award. He is a former chairperson of the National Eye Institute study section that is responsible for determining funding priorities for a large number of retinal research grants, including many related to glaucoma. He has served on scientific advisory boards for a number of academic institutions, journals, nonprofit research foundations, and biotech and pharmaceutical companies.